Chloroquine Hydroxychloroquine suspended as treatment for CoronaVirus COVID-19

The medical journal The Lancet 22 May 2020 has reported being unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19. Hydroxychloroquine is a drug that is most commonly used as an antimalarial.

Nearly 800 GP practices across the UK are now recruiting patients onto the trial, led by the University of Oxford. The trial investigating coronavirus (Covid-19) treatments via GP practices known as the PRINCIPLE trial has been halted recruitment following concerns about the safety of hydroxychloroquine. PRINCIPLE ‘is a flexible, platform trial of interventions suitable for use in the community that may prevent hospitalisation and speed recovery from Covid-19 illness

World Health Organisation (WHO) has initiated the temporary suspension of global trials that include hydroxychloroquine.